LAHORE, NOV. 2018: CCL this week signed a memorandum of understanding (MoU) with Pakistan Endocrine Society in a simple ceremony held at CCL’s Head Office in Lahore. Muhammad Akram, Commercial Director, CCL Pharmaceuticals signed the MoU along with Dr. Abbas Raza, Executive Member of Pakistan Endocrine Society.
As part of this MoU, a Medical Advisory Board has been created comprising 11 leading consultants in endocrinology, gastroenterology and cardiology, who will be working as a team to finalize the SGLT2 (sodium-glucose co-transporter 2) guidelines for Pakistan. SGLT2 inhibitors are the newest oral agents used for the treatment of diabetes and they have revolutionized the management of diabetes with cardio-protection as an added benefit.
“We have been working with Pakistan Endocrine Society (PES) from the platform of Partners in Prevention and are grateful to PES for this continued cooperation in this therapeutic area,” remarked Muhammad Akram.
Dr. Abbas Raza thanked CCL for its contribution to the prevention and management of cardio-metabolic diseases. CCL Pharmaceuticals is the 1st pharmaceutical company to introduce the SGLT2 class in Pakistan with the launch of XIGA.
For further information, please contact Muhammad Abdullah, Business Manager at muhammad.abdullah@cclpharma.net
